Two Sigma Investments LP Has $1.87 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Two Sigma Investments LP decreased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 616,800 shares of the company's stock after selling 291,801 shares during the quarter. Two Sigma Investments LP owned approximately 0.87% of Zentalis Pharmaceuticals worth $1,869,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZNTL. Corton Capital Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $32,000. Captrust Financial Advisors bought a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $33,000. Prudential Financial Inc. acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at about $39,000. Cerity Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth about $40,000. Finally, Ieq Capital LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth about $46,000.

Analyst Ratings Changes

Several analysts have recently commented on ZNTL shares. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Trading Up 3.4%

Shares of NASDAQ:ZNTL traded up $0.05 during trading on Friday, hitting $1.52. 840,975 shares of the company's stock were exchanged, compared to its average volume of 1,571,081. The firm has a market cap of $109.37 million, a P/E ratio of -0.61 and a beta of 1.61. The firm has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $2.10. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $11.16.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.67). As a group, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers purchased 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The stock was bought at an average cost of $1.40 per share, with a total value of $29,400.00. Following the purchase, the director now directly owns 281,192 shares in the company, valued at $393,668.80. The trade was a 8.07% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 1.90% of the stock is owned by corporate insiders.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.